For patients with small cell lung cancer, chest radiotherapy increases survival, decreases recurrence
the ONA take:
According to a new study published in The Lancet, patients with advanced small cell lung cancer (SCLC) experienced prolonged survival and reduced recurrence of the disease after being treated prophylactic cranial radiotherapy plus thoracic radiotherapy compared with those treated with prophylactic cranial radiotherapy alone.
In the phase 3 clinical study, researchers enrolled 498 adults with advanced SCLC who had already responded to first-line chemotherapy from 42 hospitals in Europe. Patients were randomized to receive either prophylactic cranial radiotherapy plus chest radiotherapy or prophylactic cranial radiotherapy alone. Radiation was administered over 2 weeks and patients were followed for an average of 2 years.
The researchers found that patients survival rates were similar between both groups after 1 year, but they found that after 2 years, 13% of patients treated with combination radiotherapy were alive, while only 3% of those treated with prophylactic cranial radiotherapy were alive. In addition, 20% those who received combination radiotherapy experienced recurrence in the thoracic region compared with 46% of the cranial radiotherapy group.
The authors suggest that chest radiation therapy should be considered as a treatment approach in patients with extensive small cell lung cancer who have responded to first-line chemotherapy.
SCLC patients experienced prolonged survivalafter being treated prophylactic cranial radiotherapy.
For patients with advanced small cell lung cancer, thoracic radiotherapy alongside standard treatment may boost long-term survival and reduce the likelihood of cancer recurrence in the chest, according to researchers.
Small cell lung cancer (SCLC) accounts for around 10-15% of all lung cancer cases. It is almost always caused by smoking and tends to spread rapidly to other parts of the body, meaning it is often diagnosed in its advanced stages.
- Sexual Dysfunction in Women With Cancer: A Review of Available Interventions
- Osteoporosis Medication Improves Bone Health in ADT-Treated Prostate Cancer
- Inotuzumab Ozogamicin Granted FDA Approval for Acute Lymphoblastic Leukemia
- Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose
- Risk of Some Cancers Higher in Women With a History of Periodontal Disease
- To Better Serve Patients With Cancer, Navigators Need Better Systems
- Physical Activity Improves Cognitive Function for Breast Cancer Survivors
- Risk of Lung Cancer Increases With Diets Higher in Saturated Fats
- Mechanisms Identified for Curcumin Resensitization of Cancer Cells
- Value of Type and Crossmatch Prior to Daratumumab Administration
- Affect of Daratumumab on Laboratory Blood Test Results
- Geriatric Consults Rare in Kidney Cancer Care
- Worse Survival Seen for Alternative Versus Usual Cancer Therapy
- Anorexia-Cachexia in Non-Small Cell Lung Cancer Improved With Anamorelin
- Early Recognition of Checkpoint Inhibitor-Related Pneumonitis Improves Outcomes
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|